Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
19 juil. 2023 06h00 HE
|
Catalyst Pharmaceuticals, Inc.
Vamorolone is a Promising Best-In-Class Dissociative Anti-Inflammatory Steroid Treatment for Duchenne Muscular Dystrophy Synergistic Novel Asset Leverages Catalyst's Expertise and Bolsters...
Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
20 juin 2023 06h00 HE
|
Catalyst Pharmaceuticals, Inc.
Vamorolone is Currently Under Review with the FDA (PDUFA Date of October 26, 2023) for the Treatment of Duchenne Muscular Dystrophy, a Rare Neuromuscular Disease FDA has Granted Fast Track and Orphan...
Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023
01 juin 2023 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
Reaffirms Full Year 2023 Total Revenue Guidance of Between $375 Million and $385 Million Forecasts FIRDAPSE® 2023 Net Product Revenue Guidance of Between $245 Million and $255 Million, an...
Catalyst Pharmaceuticals Announces Release of Inaugural ESG Report
01 mai 2023 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., May 01, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and...
Catalyst Pharmaceuticals Announces Third-Party Abstracts on FYCOMPA® (Perampanel) to be Presented at the Upcoming American Academy of Neurology 2023 Annual Meeting
20 avr. 2023 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., April 20, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 15, 2023
01 mars 2023 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Catalyst Pharmaceuticals to Ring the Nasdaq Closing Bell in Honor of International Rare Disease Day
22 févr. 2023 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
Spotlight On Raising Awareness for Rare Diseases on February 28, 2023 Celebrating the Tireless Contributions of Patients and Advocates who Work with the Biotech Industry to Bring New Treatments to...
Catalyst Pharmaceuticals Comments on FDA's Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra
23 janv. 2023 13h25 HE
|
Catalyst Pharmaceuticals, Inc.
Announced Earlier Today-Notice Received from ANDA Filer for FIRDAPSE® CORAL GABLES, Fla., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ: CPRX), a...
Catalyst Pharmaceuticals Notified of Abbreviated New Drug Application Filing for FIRDAPSE®
23 janv. 2023 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd
19 déc. 2022 16h10 HE
|
Catalyst Pharmaceuticals, Inc.
Acquisition Expands The Company’s Commercial Portfolio With An Established U.S. Marketed Product Company Remains Dedicated To Growth Within Neurology Through Continued Active Business Development...